The earnings call conveyed a mostly positive outlook, with significant progress in financial restructuring and regulatory advancements for narsoplimab, despite some delays and decreased income from certain operations.

Company Guidance

During the earnings call for Omeros Corporation, the company provided several key financial metrics and updates on its development programs. For the second quarter of 2025, Omeros reported a net loss of $25.4 million, or $0.43 per share, which improved from a net loss of $33.5 million, or $0.58 per share, in the first quarter of the same year. As of June 30, 2025, the company held $28.7 million in cash and investments, which was bolstered by a $20.6 million capital raise from a registered direct offering in July. The company also significantly reduced its debt, bringing down the outstanding principal on its 2026 notes from $98 million to $17 million and extending most of its debt maturities to 2029. Omeros is preparing for the anticipated approval and launch of narsoplimab, aiming for FDA approval by December 26, 2025, with potential label discussions starting in October 2025. Additionally, the company has submitted a marketing authorization application for narsoplimab to the European Medicines Agency, expecting a decision by mid-2026. Omeros is also in advanced discussions for a multibillion-dollar transaction related to its clinical assets, which could provide upfront cash sufficient to cover over 12 months of operations post-closing.

Reduction in Net Loss

Omeros reported a reduced net loss for Q2 2025 of $25.4 million, down from $33.5 million in Q1 2025.

Debt Maturity Extension

The company successfully extended its debt maturity profile by reducing the outstanding principal on its 2026 notes from $98 million to $17 million and eliminating a $20 million mandatory prepayment.

Funding and Capital Raising

Omeros raised $20.6 million through a registered direct offering, strengthening its cash position.

Narsoplimab Approval Progress

The FDA accepted the resubmission of the Biologics License Application for narsoplimab, with a revised PDUFA date set for December 26, 2025.

European Regulatory Progress

The Marketing Authorization Application for narsoplimab in TA-TMA was submitted and validated by the European Medicines Agency.

Positive Physician Feedback

Physicians have shown significant interest in narsoplimab, reflecting a strong demand for the treatment upon potential approval.

Omeros (OMER) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

OMER Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 05, 2025	2025 (Q3)	-0.45 / -	-0.56	―	―	―
Aug 14, 2025	2025 (Q2)	-0.50 / -0.43	-0.97	55.67% (+0.54)	―
May 15, 2025	2025 (Q1)	- / -0.58	-0.63	7.94% (+0.05)	―
Mar 31, 2025	2024 (Q4)	-0.57 / -0.58	-0.63	7.94% (+0.05)	―
Nov 13, 2024	2024 (Q3)	-0.70 / -0.56	-0.6	6.67% (+0.04)	―
Aug 07, 2024	2024 (Q2)	-1.14 / -0.97	-0.59	-64.41% (-0.38)	―
May 15, 2024	2024 (Q1)	- / -	-0.54	―	―
Apr 01, 2024	2023 (Q4)	-0.56 / -0.63	-0.54	-16.67% (-0.09)	―
Nov 09, 2023	2023 (Q3)	-0.61 / -0.60	-0.28	-114.29% (-0.32)	―
Aug 09, 2023	2023 (Q2)	-0.57 / -0.59	-0.49	-20.41% (-0.10)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

OMER Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 14, 2025	$4.12	$4.41	+7.04%
May 15, 2025	$3.95	$3.22	-18.48%
Mar 31, 2025	$8.22	$7.91	-3.77%
Nov 13, 2024	$4.19	$6.95	+65.87%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Omeros Corp (OMER) report earnings?

Omeros Corp (OMER) is schdueled to report earning on Nov 05, 2025, After Close (Confirmed).

What is Omeros Corp (OMER) earnings time?

Omeros Corp (OMER) earnings time is at Nov 05, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is OMER EPS forecast?

OMER EPS forecast for the fiscal quarter 2025 (Q3) is -0.45.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing